Quick Answer
Vitamin D Hair Loss Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Background/objectives Sensorineural hearing loss (SNHL) is a chronic condition with no established pharmacological treatment.
Key Takeaways
- 01Background/objectives Sensorineural hearing loss (SNHL) is a chronic condition with no established pharmacological treatment. [Mavandi M (2026)]
- 02Recent advances in drug-based therapies offer promising opportunities to prevent or treat SNHL. [Mavandi M (2026)]
- 03Multiple observational studies have demonstrated that serum 25-hydroxyvitamin D levels are significantly lower in SSNHL patients than in healthy controls, with deficiency associated with greater hearing impairment, poorer treatment response, and higher recurrence risk. [Wang Y (2026)]
- 04However, it must be emphasized that no standardized serum threshold, population-specific validation, or universally accepted predictive model currently exists; therefore, serum 25(OH)D should be regarded as a candidate-rather than an established-biomarker for SSNHL risk stratification. [Wang Y (2026)]
The current Migaku evidence database contains 2 reusable source documents for Vitamin D Hair Loss Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Background/objectives Sensorineural hearing loss (SNHL) is a chronic condition with no established pharmacological treatment. [Mavandi M (2026); evidence level 3]
- Recent advances in drug-based therapies offer promising opportunities to prevent or treat SNHL. [Mavandi M (2026); evidence level 3]
- Multiple observational studies have demonstrated that serum 25-hydroxyvitamin D levels are significantly lower in SSNHL patients than in healthy controls, with deficiency associated with greater hearing impairment, poorer treatment response, and higher recurrence risk. [Wang Y (2026); evidence level 3]
- However, it must be emphasized that no standardized serum threshold, population-specific validation, or universally accepted predictive model currently exists; therefore, serum 25(OH)D should be regarded as a candidate-rather than an established-biomarker for SSNHL risk stratification. [Wang Y (2026); evidence level 3]
- Sudden sensorineural hearing loss (SSNHL) is defined as a rapid hearing decline of ≥30 dB across at least three contiguous frequencies within 72 h, with a multifactorial etiology encompassing vascular, viral, autoimmune, and metabolic mechanisms. [Wang Y (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources